SWOG clinical trial number
CTSU/NCCTG N0733
"Randomized Phase II Trial of Capecitabine and Lapatinib with or without IMC-A12 in Patients with HER2 Positive Breast Cancer Previously Treated with Trastuzumab and an Anthracycline and/or a Taxane"
Closed
Abbreviated Title
ADVANCED: Capecitabine and Lapatinib +/- IMC-A12 for Her2+ Breast Cancer
Activated
08/15/2008
Closed
06/08/2012
Participants
CTSU
Research committees
Breast Cancer
Symptom Control and Quality of Life
Treatment
Capecitabine
Lapatinib
IMC-A12
Eligibility Criteria Expand/Collapse
The Southwest Oncology Group has endorsed this study through the Cancer Trials Support Unit (CTSU) of the National Cancer Institute.
Please contact the CTSU directly by either phone (1-888-823-5923) or on the CTSU web site (http://www.ctsu.org/) for information and registration procedures.
0.5 Cancer Control Credits
Please contact the CTSU directly by either phone (1-888-823-5923) or on the CTSU web site (http://www.ctsu.org/) for information and registration procedures.
0.5 Cancer Control Credits
Other Clinical Trials
SWOG Clinical Trial Number
S2205
ICE COMPRESS: Randomized Trial of Limb Cryocompression versus Continuous Compression Versus Low Cyclic Compression for the Prevention of Taxane-Induced Peripheral Neuroropathy
Research Committee(s)
Symptom Control and Quality of Life
Activated
03/16/2023
Accrual
21%
Open
Phase
SWOG Clinical Trial Number
S2010
A Randomized Phase III Trial Comparing Active Symptom Monitoring Plus Patient Education Versus Patient Education Alone To Improve Persistence with Endocrine Therapy in Young Women With Stage I-III Breast Cancer (ASPEN)
Research Committee(s)
Symptom Control and Quality of Life
Activated
01/17/2023
Accrual
64%
Open
Phase
SWOG Clinical Trial Number
EAQ202
Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials
Research Committee(s)
Symptom Control and Quality of Life
Activated
10/28/2021
Open
Phase